Evidence map›Paper›PMID 32740771›Full record

Observational studyEuropean journal of clinical pharmacology2020

Drug exposure for PDA closure in France: a prospective, cohort-based, analysis.

Silvia Iacobelli, Simon Lorrain, Béatrice Gouyon, Silvia Gambacorta, Nicola Laforgia, Jean-Bernard Gouyon, Francesco Bonsante

Abstract readMulticenter StudyObservational Study
PubMed Publisher
In one paragraph

Observational study in European journal of clinical pharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.9field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Use of diuretics in the neonatal period.Pediatric nephrology (Berlin, Germany) · 2021
    Review
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 3 countries.

Silvia IacobelliNéonatologie, Réanimation Néonatale et Pédiatrique, CHU La Réunion, Saint Pierre, France. silvia.iacobelli@chu-reunion.fr.ORCID http://orcid.org/0000-0002-6243-0909
Simon LorrainCentre d'Etudes Périnatales de l'Océan Indien (CEPOI, EA7388), Université de la Réunion, Saint Pierre, France.
Béatrice GouyonCentre d'Etudes Périnatales de l'Océan Indien (CEPOI, EA7388), Université de la Réunion, Saint Pierre, France.
Silvia GambacortaNeonatologia e TIN Universitaria DIMO Università Bari, Bari, Italy.
Nicola LaforgiaNeonatologia e TIN Universitaria DIMO Università Bari, Bari, Italy.
Jean-Bernard GouyonCentre d'Etudes Périnatales de l'Océan Indien (CEPOI, EA7388), Université de la Réunion, Saint Pierre, France.
Francesco BonsanteNéonatologie, Réanimation Néonatale et Pédiatrique, CHU La Réunion, Saint Pierre, France.
University of Reunion Island · REUniversity of Bari Aldo Moro · IT

Funding

European research program FEDER 2014-34018
6 · The paper itself

Abstract

purposeTo describe the exposure to drugs used for the treatment of patent ductus arteriosus (PDA) in a large cohort of preterm infants born before 32 weeks of gestation.

methodsA prospective observational cohort analysis was conducted during 2 years in 28 French level 3 NICU using the same computerized order-entry system. The main outcome was "a medically treated PDA," defined as exposure to ibuprofen, indomethacin, or paracetamol prescribed with the indication of PDA closure. Secondary outcomes were as follows: time of the first treatment administration; total exposure to furosemide during hospitalization; and rate of PDA refractory to pharmacological closure.

resultsThe study cohort consisted of 2614 infants. Among them, 474 (18.1%) received a medical treatment for PDA, with a mean postnatal age at treatment of 4.3 ± 6.6 days. The drug used as a first-line treatment was ibuprofen in 89.5% and paracetamol in 10.5%. One hundred and ninety-five infants (7.4%) had a PDA refractory to pharmacological closure. At the multivariate analysis, factors associated with PDA refractory to pharmacological closure (OR; 95% CI) were as follows: gestational age (GA) (0.81; 0.72-0.90), paracetamol as the first-line treatment (0.32; 0.15-0.68), and pharmacological treatment before 48 h of life (0.63; 0.43-0.94). 24.6% of the study cohort was exposed to furosemide (cumulative dose 6.5 ± 12.6 mg/kg). Variables significantly associated with higher cumulative doses of furosemide were lower GA and ibuprofen treatment (both p < 0.0001).

conclusionDrug utilization patterns in infants with PDA vary among centers. Pharmacoepidemiology studies can provide new information on factors associated with PDA refractory to medical treatment.

Indexed as

AcetaminophenAdministration, OralDrug ResistanceDrug UtilizationDuctus Arteriosus, PatentFemaleFranceFurosemideHospitalizationHumansIbuprofenIndomethacinInfant, NewbornInfant, PrematureIntensive Care Units, NeonatalMaleAcetaminophenFurosemideIbuprofenIndomethacinDrug utilizationNeonatal diureticsNeonatal intensive care unitNon-steroidal anti-inflammatory drugsVery-low-birth-weight-infants

Identifiers

PMID32740771
OpenAlexW3046340012

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.